Targeted drug shows promise for rare genetic cancers, but study halted early
Disease control
Terminated
This study tested the drug niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific PALB2 gene mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stopped early, so results are …
Phase: PHASE2 • Sponsor: Tempus AI • Aim: Disease control
Last updated May 15, 2026 11:56 UTC